Utilization and Comparative Effectiveness of Caspofungin and Voriconazole Early after Market Approval in the US

被引:9
作者
Ascioglu, Sibel [1 ]
Chan, K. Arnold [1 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
关键词
EMPIRICAL ANTIFUNGAL THERAPY; LIPOSOMAL AMPHOTERICIN-B; OFF-LABEL; FUNGAL-INFECTIONS; PROPENSITY SCORE; ASPERGILLOSIS;
D O I
10.1371/journal.pone.0083658
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives: Both caspofungin and voriconazole were initially approved by the FDA with very narrow indications. Our aim was to evaluate the utilization patterns and comparative effectiveness of these agents early after marketing before any labeling change occurred. Methods: This was a retrospective cohort study utilizing a large healthcare database in the United States. Patients who received at least one dose of systemic antifungal agent between the years 2001 and 2003 were included. Information was available for each hospital-day including underlying conditions, medications, procedures and disease severity scores. Tests for proportions, trend tests and logistic regression were used for evaluation of utilization. Propensity score analysis was used in comparison of mortality. Results: The study cohort included 381,245 patients with serious underlying conditions. In just two years after marketing, caspofungin and voriconazole use increased to 40% of the total systemic antifungal consumption. However, only 3.4% of caspofungin and 12.5% of voriconazole were used as indicated in labeling. In the propensity score analyses, caspofungin was associated with 7% decrease in mortality (OR: 0.93 95% CI: 0.85-0.98). Voriconazole use was not found to be associated with mortality (OR: 1.95% CI: 0.89-1.12) Conclusions: Caspofungin and voriconazole were mostly used of unapproved indications immediately after their marketing. Although unapproved drug use might be due to a crucial need by clinicians, this may create problems in further antifungal drug development. Our results suggest a survival benefit with caspofungin; however, similar comparative effectiveness studies must be repeated using more recent data.
引用
收藏
页数:7
相关论文
共 32 条
[1]  
Averill RF., 2003, What Are APR-DRGs? An Introduction to Severity of Illness and Risk of Mortality Adjustment Methodology
[2]   Disseminating innovations in health care [J].
Berwick, DM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (15) :1969-1975
[3]   A PHARMACOLOGIC GUIDE TO CLINICAL USE OF AMPHOTERICIN B [J].
BINDSCHADLER, DD ;
BENNETT, JE .
JOURNAL OF INFECTIOUS DISEASES, 1969, 120 (04) :427-+
[4]   National trends in cyclooxygenase-2 inhibitor use since market release - Nonselective diffusion of a selectively cost-effective innovation [J].
Dai, CL ;
Stafford, RS ;
Alexander, C .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (02) :171-177
[5]   Burden of aspergillosis-related hospitalizations in the United States [J].
Dasbach, EJ ;
Davies, GM ;
Teutsch, SM .
CLINICAL INFECTIOUS DISEASES, 2000, 31 (06) :1524-1528
[6]  
de With Katja, 2005, BMC Clin Pharmacol, V5, P1
[7]   Fluconazole for the prevention of fungal infections: Get ready, get set, caution [J].
Fanaroff, AA .
PEDIATRICS, 2006, 117 (01) :214-215
[8]   USE OF ANTIFUNGAL THERAPY IN HOSPITALIZED-PATIENTS .1. RESULTS PRIOR TO THE MARKETING OF FLUCONAZOLE [J].
GRASELA, TH ;
GOODWIN, SD ;
PASKO, MT ;
WALAWANDER, CA ;
RAEBEL, MA .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (02) :252-260
[9]   An audit of the use of antifungal agents [J].
Gutierrez, F ;
Wall, PG ;
Cohen, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 (01) :175-185
[10]   Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].
Herbrecht, R ;
Denning, DW ;
Patterson, TF ;
Bennett, JE ;
Greene, RE ;
Oestmann, JW ;
Kern, WV ;
Marr, KA ;
Ribaud, P ;
Lortholary, O ;
Sylvester, R ;
Rubin, RH ;
Wingard, JR ;
Stark, P ;
Durand, C ;
Caillot, D ;
Thiel, E ;
Chandrasekar, PH ;
Hodges, MR ;
Schlamm, HT ;
Troke, PF ;
de Pauw, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415